CTRI/2019/02/017473招募中未知
An Observational, Open-label, Parallel Group Trial Comparing the effects of Azilsartan and Benidipine on arterial stiffness in newly diagnosed hypertensive
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Subjects, newly diagnosed with Essential Hypertension of Stage 1 with SBP ranging between 140-159 mmHg and/or DBP ranging between 90-99 mmHg as per JNC classification
排除标准
- •1) Subjects with secondary hypertension
- •2)Subjects with known CV risk factors, diabetes mellitus.
- •3)Subjects with any significant abnormalities on a 12-lead ECG
- •4)Subjects with known neuromuscular disorders
- •5)History of alcoholism (alcohol abuse) and cannot refrain from alcohol consumption during the study period.
- •6)History of smoking ( >1 pack per day or >20 cigarettes) and cannot refrain from smoking during the study period
研究者
相似试验
进行中（未招募）
不适用
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHon-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-SEGenmab A/S273
进行中（未招募）
1 期
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHon-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-GBGenmab A/S273
进行中（未招募）
1 期
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.on-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-FRGenmab A/S
进行中（未招募）
不适用
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy. - zalutumumab in non-curable patients with SCCHon-Curable Squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-EEGenmab A/S273
进行中（未招募）
1 期
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy.Ensayo abierto, aleatorizado, de grupos paralelos con zalutumumab , un anticuerpo monoclonal humano anti-receptor de EGF, en combinación con los mejores cuidados de soporte, frente a los mejores cuidados de soporte solamente, en pacientes con carcinoma escamoso de cabeza y cuello incurable que no han respondido a la quimioterapia estándar basada en platino. - zalutumumab in non-curable patients with SCCHCarcinoma escamoso de cabeza y cuello incurable Non-Curable Squamous Cell Carcinoma of the Head and NeckMedDRA version: 8.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2006-002472-17-ESGenmab A/S273